Etoricoxib + Placebo

ApprovedUNKNOWN

0 views this week 0 watching💤 Quiet

Interest: 39/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Postherpetic Neuralgia

Conditions

Postherpetic Neuralgia, Neuralgia

Trial Timeline

Mar 1, 2011 → Apr 1, 2012

NCT ID

NCT01264237

About Etoricoxib + Placebo

Etoricoxib + Placebo is a approved stage product being developed by Merck for Postherpetic Neuralgia. The current trial status is unknown. This product is registered under clinical trial identifier NCT01264237. Target conditions include Postherpetic Neuralgia, Neuralgia.

What happened to similar drugs?

3 of 7 similar drugs in Postherpetic Neuralgia were approved

Approved (3) Terminated (1) Active (4)

✅QUTENZAAstellas PharmaApproved

🔄Placebo + Pregabalin SR tablet 165mg/day + Pregabalin SR tablet 330mg/day + Pregabalin SR tablet 660mg/dayJiangsu Hengrui MedicinePhase 3

✅Lyrica (pregabalin) + PlaceboPfizerApproved

🔄Placebo + Pregabalin + Pregabalin + PregabalinPfizerPhase 3

🔄pregabalinPfizerPhase 3

✅pregabalinPfizerApproved

🔄HSK16149 20mg BID + HSK16149 40mg BID + Placebo BIDHaisco Pharmaceutical GroupPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01264237	Approved	UNKNOWN	Mar 1, 2011	Apr 1, 2012	Postherpetic Neuralgia

Competing Products

20 competing products in Postherpetic Neuralgia

See all competitors

Product	Company	Stage	Hype Score
QUTENZA	Astellas Pharma	Approved	43
KHK6188 + Placebo	Kyowa Kirin	Phase 2	35
ONO-1110 + Placebo	Ono Pharmaceutical	Phase 2	39
Placebo + Pregabalin SR tablet 165mg/day + Pregabalin SR tablet 330mg/day + Pregabalin SR tablet 660mg/day	Jiangsu Hengrui Medicine	Phase 3	36
MK-8291 + Placebo	Merck	Phase 1	29
ADL5747 + Placebo + Pregabalin	Merck	Phase 2	27
MK0759	Merck	Phase 2	27
MK0686	Merck	Phase 2	27
Comparator: pregabalin + Comparator: Placebo (unspecified)	Merck	Phase 1	29
Lyrica (pregabalin) + Placebo	Pfizer	Approved	43
RN624 + RN624 + Placebo	Pfizer	Phase 2	35
T-62	Pfizer	Phase 2	27
pregabalin + pregabalin/PF-00489791 + Placebo	Pfizer	Phase 2	35
PH-797804 + Placebo	Pfizer	Phase 2	35
Placebo + Pregabalin + Pregabalin + Pregabalin	Pfizer	Phase 3	40
pregabalin	Pfizer	Phase 3	40
pregabalin	Pfizer	Approved	35
T-62 Dose 1 + T-62 Dose 2	Pfizer	Phase 2	27
HSK16149 20mg BID + HSK16149 40mg BID + Placebo BID	Haisco Pharmaceutical Group	Phase 3	40
Levetiracetam	UCB	Phase 2	35